Quantcast

Latest Sirolimus Stories

2011-04-12 13:59:00

EAST HANOVER, N.J., April 12, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of Afinitor® (everolimus) tablets for the treatment of patients with advanced neuroendocrine tumors (NET) of pancreatic origin. The recommendation was provided after presentation of data from the everolimus RADIANT (RAD001 In Advanced...

2011-04-05 21:22:08

Penn study offers novel drug combination to halt tumor growth Researchers at the University of Pennsylvania School of Medicine may have found a way to turn an adaptive cellular response into a liability for cancer cells. When normal cells are starved for food, they chew up existing proteins and membranes to stay alive. Cancer cells have corrupted that process, called autophagy, using it to survive when they run out of nutrients and to evade death after damage from chemotherapy and other...

2011-03-23 08:00:00

HONG KONG, March 23, 2011 /PRNewswire/ -- OrbusNeich today announced that 12-month outcomes data from a subset analysis of the global e-HEALING registry were published online ahead of print in the Journal of Interventional Cardiology and demonstrated the effectiveness and safety of the company's Genous Stent in diabetic patients, with low definite and probable stent thrombosis (ST) comparable to non-diabetics. The study investigated the 1,236 diabetic patients from the e-HEALING registry,...

2011-03-21 02:00:00

HONG KONG, March 21, 2011 /PRNewswire/ -- OrbusNeich today announced that it has filed a lawsuit in the Netherlands against Dr. Pavel Cervinka and Masaryk Hospital in Usti nad Labem, Czech Republic, where Dr. Cervinka is head of the hospital's Cardiology Department. The suit relates to a clinical study conducted at the Masaryk Hospital, in which Dr. Cervinka was the Principal Investigator, which purported to randomly compare OrbusNeich's Genous stent with a bare metal stent for treatment of...

2011-03-17 12:29:02

WHAT: Sirolimus, a drug currently used to help prevent transplant rejection, can improve lung function and quality of life in individuals living with the lung disease lymphangioleiomyomatosis (LAM), according to the results of a new study sponsored and conducted in part by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. "Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis," will be published online March 16 in the New England Journal of...

2011-03-17 12:27:36

Researchers at the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center have found that the FDA-approved drug sirolimus, used primarily to prevent rejection in organ transplant patients, stabilized lung function in women with lymphangioleiomyomatosis (LAM). The Multicenter International LAM Efficacy of Sirolimus (MILES) trial was the first randomized, controlled study designed to develop a therapy for this life-threatening illness, which currently has no cure or...

2011-03-14 08:00:00

HONG KONG, March 14, 2011 /PRNewswire/ -- OrbusNeich today announced the launch of the CE marked Azule Cobalt Chromium Stent. The Azule Stent combines the proven stent design of its predecessor, the company's Blazer(TM) Cobalt Chromium Stent, with a delivery system with enhanced crossability and flexible deliverability. Azule features OrbusNeich's unique Dual Helix stent design, offering conformability and radial strength on thin, flexible and low-profile cobalt chromium stent struts....

2011-03-09 14:07:33

A study from Karolinska Institutet has shown that the body's ability to break down medicines may be closely related to exposure to sunlight, and thus may vary with the seasons. The findings offer a completely new model to explain individual differences in the effects of drugs, and how the surroundings can influence the body's ability to deal with toxins. The study will be published in the scientific journal Drug Metabolism & Disposition and is based on nearly 70,000 analyses from...

2011-02-28 08:00:00

HONG KONG, Feb. 28, 2011 /PRNewswire/ -- OrbusNeich today announced that the next-generation Sapphire II coronary dilatation catheter is now commercially available, following CE Mark (Conformite Europeenne) approval. Sapphire II offers an ultra-low crossing profile across a broad range of configurations, including 1.0 mm diameter balloons and 150 cm shaft working length versions. Sapphire II features a flexible, supple balloon material for slender rewrap; an XD (eXtra Durable) shaft for...

2011-02-28 07:00:00

SINGAPORE, Feb. 28, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced that its novel dual mTOR/PI3 Kinase inhibitor SB2343 demonstrated excellent pharmacokinetic/pharmacodynamic (PK/PD) properties leading to significant anti-tumor efficacy in rapamycin-sensitive and resistant xenograft models. In vivo and in vitro data on SB2343 were presented at American Association of Cancer Research (AACR) Special Conference on Targeting PI3K/mTOR Signaling in Cancer held in San Francisco. SB2343 is...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.